Medical devices are being developed continuously and their developers are under pressure to provide better evaluations of their products. Early assessment gathers the preliminary evidence to estimate clinical, financial, organizational, and social/ ethical consequences of a particular technology. It seems a useful tool in predicting the potential of medical devices at the stage in which it can be adapted to fit the environment or the environment can be prepared for the technology. If the potential is low, further development can also be stopped. Although early assessment is recognized as an important part of medical device development process, there are many uncertainties in its nature and regarding the methods that are being used for its purpose. OBJECTIVE: To review different methods and their use in the early assessment of medical technologies. METHODS: An extensive systematic literature review of different early assessment methods. The authors systematically searched: computerised databases; published bibliographies of related topics; citations in articles reviewed; and references provided by colleagues. RESULTS: We identified 40 studies that met the inclusion criteria. 18 papers were either systematic literature Reviews (5) or theoretical papers (13). 10 papers were addressing specific applications of early assessment methodologies, and 12 papers were addressing theoretical concepts combined with examples. Those 22 articles were analysed and categorised with regard to the stage of development of the technology, innovation type, perspective and aims of the analysis. Aims, outcome and uncertainties with regard to the outcome of the analysis were assessed. CONCLUSIONS: There is a need to clarify and communicate the aims and value of early assessment methods of medical devices to developers and policy makers, if early assessment methods are to become an integrated part of early activities in the development process.
Cost-effectiveness analysis is a well recognized tool to support decisions about resource allocation in health care, particularly in the context of collectively funded health systems. When a new technology is restricted based on cost-effectiveness (because it is deemed too expensive relative to its expected benefits) a potential conflict can arise between the social interests (i.e. maximization of the population health subject to fixed budget constraint) and individuals who want to maximize their own health or utility. It has been previously argued that decisions that consider heterogeneity add value to the health care system. On the one hand, if a centralized decision process is implemented (e.g. NICE in the UK), subgroup analysis is appropriate. On the other hand, if a decentralized process is to be implemented, the effect of unrestricted choices on the social interests must be assessed. I have recently presented an analytical approach to estimate the expected health forgone (or gained) as a consequence of implementing a decentralized decision process. In the simplest case it was assumed that social planners and patients focus on the same metric of health, i.e. patients maximise health (for example, QALYs) and social decision makers maximise net health (net QALYs). This piece of work examines the case where patients choose according to a different maximand. The analysis shows that if a single and different argument of the patient's maximization function can be identified, the expected net health benefits forgone (or gained) from implementing unrestricted choices can be estimated as an extension of the base-case analysis. It also highlights the role of a robust estimation of the joint distribution of potential outcomes, discussing gaps that require further research. The contribution of this analysis for policy decisions about individualized care is illustrated with a stylized numerical example. Reimbursement and research decisions about the utilisation of health care interventions can be formally characterised using methods for economic evaluation. Reimbursement decisions are informed by establishing the expected cost-effectiveness of the intervention. Research decisions are informed by establishing the expected value of additional information (the cost of uncertainty). Price negotiation can be used to alter conclusions about the benefits of reimbursement and the need for further research. In practice each of these elements may be considered separately, but they could routinely be combined within a single evaluation. Previous research has shown (i) the impact of future changes on the payoff from reimbursement in the presence of irrecoverable costs and uncertainty that will be resolved over time, and; (ii) how the reimbursement and research decisions interact in terms of the ability to acquire additional information and the impact of delay on the payoffs and the size of the populations that can benefit. The objective of this paper is to bring together established methods, using a consistent set of notation, to describe a general algebraic framework. The aim is to show systematically how irrecoverable costs, uncertainty that can be resolved through research and uncertainty that will be resolved over time can be formally incorporated in an integrated framework to estimate both cost-effectiveness and the value of further research that reflects the interaction between the reimbursement and research decisions. Furthermore we show how effective price negotiation would affect the payoff and ranking of the alternative policy options. A simple numerical example is used to demonstrate the application of this general algebraic framework and how the results might be presented to decision makers. The advantage of a single integrated framework is that reimbursement, research and pricing decisions can be informed simultaneously, transparently and consistently.
PRM168 AN INTEGRATED FORMAL FRAMEWORK FOR REIMBURSEMENT, RESEARCH AND PRICING DELIBERATIONS IN HEALTH TECHNOLOGY ASSESSMENT

PRM169 INTERNAL AND EXTERNAL VALIDITY IN ECONOMIC MODELING: CONSIDERATIONS BASED ON A PUBLISHED EXAMPLE
Porzsolt F University of Ulm, Ulm, Germany OBJECTIVES: Economic modeling is an established tool used for allocation of health care resources. Modeling was designed to demonstrate the influence of variables on defined outcomes (e.g. cost-effectiveness) in complex systems. Valid information for health care decisions can be obtained if five types of bias can be avoided: selection-, performance-, attrition-, detection-, and sampling-bias. In this study the validity of results derived from economic modeling is investigated addressing these five types of possible biases. METHODS: A published economic model of costs and benefits of drug treatment in mild-to-moderate Alzheimer's disease (Guo et al., J Med Econ 2010; 13:641-654) was used for this analysis. Nine questions were asked to confirm the validity of the obtained results. Internal validity was tested by checking the first four of the above types of bias, external validity by checking for a possible sampling bias. RESULTS: The presented model is flawed by absence of an explicit study question. Selection bias cannot be excluded as the patient data were obtained from pooled clinical trials and other sources. Performance bias is likely as the outcomes in patients extracted from pooled clinical trials differed considerably to the outcomes of patients treated outside of trials. A detection bias is likely as observed data were compared with extrapolated data. Also the external validity of the study is likely to be impaired as the patients profiles were not derived from real world conditions but from patients enrolled in two clinical trials. CONCLUSIONS: This appraisal shows that phrasing a study question is essential for selection of the appropriate study method. Economic modeling is useful to discuss models and to generate hypotheses but always implies a high risk of bias. Therefore, results from modeling should only be accepted when internal as well as external validity of the used method has been confirmed. 
PRM170 OPTIMIZING PUBLIC HEALTH DECISION OVER TIME: A DYNAMIC BUDGET OPTIMIZATION MODEL WITH MULTIPLE CRITERIA DECISION MAKING
Global Market Access Solutions, St Prex, Switzerland
To guide health care decision, modeling efforts have mainly focused on cost-effectiveness appraisals (CEAs) between two mutually exclusive interventions. As CEAs do not document the impact of interventions on health care budget, they are generally complemented with budget impact analysis (BIAs). BIAs provide financial projections only and do not detail the beneficial health effect an intervention may have on the population targeted. Additionally, decision makers may have different and several competing preferences and priorities on what constitutes the population health value of an intervention. A typical example is the public health impact of large childhood vaccination campaigns. Reduction of incidence, prevalence, hospitalizations, deaths, costs, etc. are the many criteria assessed by decision makers beyond the QALYs gained when they contemplate vaccination campaigns. In this research, we design a transparent dynamic budget optimization model based on a multi-criteria decision making framework. The model is a sequential multibirth cohort model with yearly cycle and adaptable time-horizon (from 3 years onwards). Optimization is realized yearly based on the population outcomes achieved the year before, the annual budget constraints and through different combinations and weightings of decision preferences. Decision maker preferences can be weighted on number of cases avoided, GP visits avoided, hospitalizations avoided, length of in-hospital stay reduction, number of in-hospital beds avoided, number of death avoided, Life-Years gain and QALYs gain. The model is intended to address specific questions that usually emanate from decision makers confronted with the introduction of mass vaccination campaigns: What is the yearly budget needed to achieve specific public health goals? What are the yearly and overall expected outcomes at the population level (i.e. the public health impact or in others words, the return-on-investment in terms of public health benefit)? Which intervention should be given additional (less) resources to maximize (minimize) impact if the available budget is increased (decreased)?
PRM171 OPTIMAL SHOPPING: AN EVAUATION OF DECISION RULES IN COST-EFFECTIVENESS ANALYSIS (CEA)
McKenna C 1 , Claxton K threshold, and 2) the health effects of the new technology with the health effects of those technologies which must be displaced to accommodate its additional costs. The performance of each is evaluated through a simulation exercise, which using shopping at the supermarket as an analogy to the health care system. An initial basket of goods represents the initial allocation and specifies the budget constraint. The task is to improve the contents of the basket by examining other things on the shelves and applying one of the decision rules. Performance is measured by: 1) how close each can get to the optimal basket (a MP solution), and 2) how quickly each improves the initial basket. We explore when each decision rule performs at its best and when one is likely to outperform the other. This includes: indivisibly of technologies and programmes, size of the budget relative to programme costs, the efficiency of exiting technologies; the type of information available to decision makers and whether they are able to learn from examining more products. This helps to identify where additional information (e.g., a better estimate of the threshold) might be most valuable.
PRM172 THE VALUE OF PERSONALIZED MEDICINE: IT IS MORE ABOUT UNVEILING THE PERFORMANCE OF THE COMPANION DIAGNOSTIC
Ethgen O University of Liege, Liege, Belgium Personalized medicine (PM) is notably typified by the development of companion diagnostic tests to guide optimal treatment selection. PM has thus the potential to dramatically improve patients' outcomes and optimise allocation of resources. However, very few attempts exist that transparently include diagnostic test performance such as Sensitivity (Se) and Specificity (Sp) into cost-effectiveness and budget impact models. This research proposes an analytical framework to unveil diagnostic added-value according to different diagnostic performance scenario. The framework is based on a decision tree and compares two hypothetical treatments N vs. C. N is a new treatment associated with a companion diagnostic test T. C is the current standard of care not associated with any test. T selects the likely responding patients based on the presence (Tϩ) or absence (TϪ) of a predictive sign of response to N (a distinctive biomarker for instance). We demonstrate that it is the prior prevalence of the sign within the target population coupled with the expected effectiveness differential between N and C in true positive patients and with the performance of the test (Se and Sp) that are the fundamental determinants of the potential value of a PM strategy. An extension of the model to the case of 2 competing PM strategies (and thus 2 competing tests) is shown. We conclude that companion diagnostic test performance is key to achieve the promises of PM. This analytical framework allows payers, HTA bodies and manufacturers to gauge the potential value and financial impact of a PM strategy at all stage of its development. 
PRM173 ON THE PROBABILITY OF INTERTEMPORAL INDIFFERENCE
Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen , The Netherlands
Issues on discounting health effects have spurred debates on appropriate decision rules. Consensus is that empirically observed rates of time preference be incorporated in analysis. The latter, however, is known to suffer from cognitive limitations. The human nervous system perceives how long sensory events last and the latter impact on perceptual decision making which is the act of choosing from a set of alternatives on the basis of available sensory evidence; in our case the indifference balance between present and future consumption. Statistical tools for such purposes are however scarce and normality assumptions often fail to hold. We therefore derive a stochastic distribution by maximum entropy principle(MaxEnt). A MaxEnt distribution is one which best represents the current state of knowledge. Furthermore, MaxEnt distributions minimize the amount of prior information built into the distribution. Such distributions are usually sought by maximization of entropy constrained on what is known. In our case, we assume that the expected indifference amount at time t compared to an amount, y 0 , now is given by E(Y(t))ϭy 0 /w(t) where w(t) is a general time-inhomogeneous discount weight. With that constraint and the usual probability constraints, we derive a maximum entropy distribution for such a future amount. That is, we provide a closed-form distribution of the probability that an individual is indifferent between some quantity Y(t)ϭy at time t and a quantity Y(0)ϭy 0 now given E(Y(t))ϭy 0 /w(t).
PRM174 THE NEED TO CONDUCT FUTURE RESEARCH ON THE BENEFIT OF THE PROSTATE SPECIFIC ANTIGEN SCREENING TEST USING THE VALUE OF INFORMATION FRAMEWORK
Reese ES, Mullins CD University of Maryland School of Pharmacy, Baltimore, MD, USA OBJECTIVES: Prostate cancer (PC) is the second most common cancer in men worldwide and the second leading cause of cancer deaths in men in the United States. Recently, the prostate specific antigen (PSA) test used to screen and diagnosis PC has been questioned due to concerns regarding clinical utility and its inability to accurately identify men with PC. This research aims to estimate the Value of Information (VoI) of the PSA screening research and to determine whether future PSA screening research should be focused on specific populations. METHODS: This research uses the Minimal Modeling Approach (MMA) in order to determine the expected value of information for PSA research. The population expected value of information (pEVI) for racial (African Americans and non-African Americans) and age (65-75 years, 76-85 years, Ͼ85 years) subgroups will be determined. Investigators will model survival based on published randomized controlled trials of PSA screening and will use data from the Surveillance Epidemiology and End-Result (SEER)-Medicare dataset for both survival and costs. Investigators will structure analyses by modeling the net benefit of men who received a prostate specific antigen screening exam between 2000 and 2007. RESUTS: VoI is recognized for providing a framework for estimating the expected benefits of clinical research. Due to the controversy surrounding the PSA screening test, patients and clinicians are challenged when trying to make informed decisions regarding diagnosis and treatment of PC. CONCLUSIONS: This research seeks to determine where the greatest return on research investment would provide a more accurate evidence base for PSA screening for PC.
PRM175 IDENTIFICATION AND TRANSLATION OF CULTURALLY BOUND TERMS IN PATIENT REPORTED OUTCOME MEASURES
Simpson H, Two R, Verjee-Lorenz A, Clayson D PharmaQuest Ltd, Banbury, UK Patient reported outcome (PRO) measures typically undergo a precise and detailed translation process which involves the input of translators, investigators, project managers and developers in order to produce the most accurate and fluent translation possible. In order for the pooling of data from international clinical trials to be possible, it is important that translations of a PRO measure mean the same to all respondents, not just in terms of the phrasing, but also in terms of the intensity and nuance of the phrases used. It is often the case that terms used frequently in PRO measures will have a direct and literal translation into the target language. However, problems can occur when terms used in the source text are culturally bound -i.e., when the direct translation of a term has a different meaning than that of the source text, in terms of intensity or connotations, or is used in a different way. For example, the term 'frustrated' has a direct translation in most languages; however, this term has a stronger meaning in some countries and can refer to a mental health issue. Issues can also arise when there is no equivalent of the source term in the target language. We will discuss common terms, expressions and nuances that are frequently used in PRO measures and how their meaning can be different across varying languages and cultural backgrounds. We will examine how to preempt these issues and how to avoid the mistranslation of culturally bound terms, by discussing the importance of detailed concept elaboration documents, input from the instrument developer, and in-depth pilot testing and cognitive debriefing. By using these methods it is possible to accurately anticipate these potential issues and explore alternative ways of conveying the intended meaning.
PRM176 THE VALUE OF FURTHER RESEARCH: THE ADDED VALUE OF INDIVIDUAL-LEVEL DATA
Saramago P University of York, York, North Yorkshire, UK OBJECTIVES: Judgements based on average cost effectiveness estimates may disguise sources of heterogeneity that should be reflected in decision making. Making decisions considering between patient heterogeneity has been proved consistent with an efficient use of limited resources. Although individual level data (IPD) is often not available to inform decision models, these provide unbiased and more precise estimates, particularly in the presence of heterogeneity. This paper seeks to assess the added value of having access to IPD, compared to using aggregate data (AD) only, in appropriately performing subgroup value of information analysis. METHODS: This paper develops a framework that informs the understanding of the implications of considering IPD when assessing the value of additional research in the absence and in the presence of mutually exclusive population subgroups. RESULTS: The developed framework explores the capabilities of the available evidence (i.e. IPD and AD) in guiding and in quantifying the value of further research in the absence and presence of subgroups. Issues around the optimal number of subgroups and for which population subsets should further research be undertaken are discussed. These exercises are supported by a motivating example on the cost effectiveness of child accident prevention programmes. CONCLUSIONS: The use of IPD rather than AD estimates may influence not only the extent to which an appropriate understanding of existing heterogeneity is attained, but, more importantly, it may shape approval decisions for particular population subgroups and judgements of furtherresearch. 
PRM177 WHAT IS THE ROLE OF EARLY HEALTH TECHNOLOGY ASSESSMENT OF BIOMARKERS IN THE PRE-CLINICAL DEVELOPMENT PHASE? A REFLECTION ON LESSONS LEARNED WITH MULTIPLE MYELOMA
OBJECTIVES:
Biomarkers associated with treatment efficacy and safety can be used to develop pharmacogenomic tests. However, translation of the evidence into clinical practice is difficult due to barriers to development and the difficulty to demonstrate clinical and economic utility. Health technology assessment (HTA) methodology may be used to inform decisions at many points during the product lifecycle. We assessed the role of HTA in the development phase of pharmacogenomic tests in multiple myeloma. METHODS: Early-Stage hta was conducted separately for two clinical applications of biomarkers: 1) a safety-based companion diagnostic, and 2) a prognostic test. We reviewed the methods that were useful in answering the questions about the health benefits and costs of the intervention and comparators strategies in each scenario were reviewed. RESULTS: An evidence-based approach was applied for both scenarios. Using literature reviews and A492
